Twitter | Search | |
Neil Sengupta
Gastroenterologist at the University of Chicago, Interests in GI bleeding, diagnostic testing in GI and liver diseases, benefits of
460
Tweets
519
Following
756
Followers
Tweets
Neil Sengupta Dec 6
Congrats!!
Reply Retweet Like
Neil Sengupta retweeted
Anjana Pillai Dec 4
Great open forum discussion with our GI fellows about how to become a successful clinical educator by Dr. Vinny Arora
Reply Retweet Like
Neil Sengupta retweeted
Tyler Berzin MD, FASGE Nov 1
1/2 Lot of promise (?hype), & some early clinical data , but much more needed. We are conducting tandem colo RCT ( outcome measures incl. adenoma miss rate, adenomas per colonoscopy..). Small rectosigmoid polyps excluded. Other RCTs also starting up.
Reply Retweet Like
Neil Sengupta Oct 31
Replying to @GI_Pearls @AnnalsofIM
Agree that comparison of high dose and non high dose PPI showed no diff in mortality and rebleeding. Not sure exactly why evidence was downgraded here (low to mod quality). Also no clue why PICO didn’t specifically compare high dose to low dose PPi after endoscopic therapy
Reply Retweet Like
Neil Sengupta Oct 31
Replying to @GI_Pearls @AnnalsofIM
Good discussion! The PICO which supports Infusion shows mortality benefit of high dose PPIs (bolus and 72hr gtt) but this was compared to no treatment (or H2b) which isn’t a helpful comparison
Reply Retweet Like
Neil Sengupta Oct 31
Don’t know yet - we don’t have trials comparing risk stratification based management to clinical judgement alone. BUT we do know that identification of low risk UGIB through GBS can avoid unnecessary hospitalizations and save $$$.
Reply Retweet Like
Neil Sengupta Oct 31
Great quest! limited data on this topic, but PCC is second line or salvage for DOAC related GIB after selective reversal agents (praxbind, andexxa). But the vast majority of the time, reversal is not needed - resuscitation and waiting for DOAC to clear is enough. No role for FFP!
Reply Retweet Like
Neil Sengupta Oct 30
Exciting tech, but we need high quality RCT data to show that AI works to increase ADR and other QI parameters. E.g. - the first lesion in example below is classified as "non-neoplastic" by machine, but clearly appears like a sessile serrated polyp to my eyes (which I trust more)
Reply Retweet Like
Neil Sengupta Oct 30
Unbelievably scary how easily advanced lesions can be missed! Stresses the importance of high quality retroflexion and getting a BBPS of 3 in right colon
Reply Retweet Like
Neil Sengupta Oct 30
Moving towards BID for mostly all
Reply Retweet Like
Neil Sengupta Oct 30
Risk stratification is critical for efficient triage of patients with GI bleeding. My approach to integrating pre-endoscopic risk scores into practice in
Reply Retweet Like
Neil Sengupta Oct 29
Very proud of Dr. Natalie Tapaskar () on her excellent oral presentation on the risks and benefits of resumption of anticoagulants following hospitalization for GIB
Reply Retweet Like
Neil Sengupta retweeted
Amy Oxentenko M.D. Oct 29
The time (in years) it will take an endoscopist to detect CRC dependent on their quintile and volume of cases per year. The J.Edward Berk Distinguished Lecture by on .
Reply Retweet Like
Neil Sengupta retweeted
Mark B. Pochapin, MD Oct 29
Dr. Lynn Butterly states that younger patients age 45-49 have advanced adenomatous at the same rate as older patients age 50-54. We need to assess how this effects when to start screening (?age 45) and why this is happening.
Reply Retweet Like
Neil Sengupta Oct 29
Higher clinically significant sessile serrated polyp detection rates (CSSDR > 7%) were associated with lower post colonoscopy colon cancer (HR 0.37) by Anderson et al
Reply Retweet Like
Neil Sengupta Oct 28
Congrats to Dr. Natalie Tapaskar on her award winning poster comparing GI bleeding outcomes for patients on Warfarin vs DOAC ⁦
Reply Retweet Like
Neil Sengupta retweeted
Elliot Tapper Oct 19
What is ? This is for patients & anyone who has ever asked: ❓ What is it ❓ Where did it come from? ❓Why do I feel this way? ❓ Am I dying? A
Reply Retweet Like
Neil Sengupta Oct 18
Replying to @NehaNigamMD
Insightful point
Reply Retweet Like
Neil Sengupta retweeted
Ziad Gellad, MD MPH Oct 17
Surgery works in the right population of patients with refractory GERD - Privileged to have participated in this important trial at the
Reply Retweet Like
Neil Sengupta retweeted
Elliot Tapper Oct 11
Who will be diagnosed with hepatic encephalopathy? Highlights 1⃣Overall rate: 11.6/100 patient-yrs 2⃣Highest risk: 👉varices or ascites (26.1/100 PY) 👉Alcohol-related (17.6) 👉ESRD (14.7) 3⃣Lowest risk: pts w/early GI involvement OA link
Reply Retweet Like